Observational study on Epithelioid Haemangioendothelioma
The Evaluation of Cytokines and Hormones as Biomarkers for Epithelioid Haemangioendothelioma and Generation of Patient-derived Preclinical Models to Assess the Activity of Anticancer Agents and Validate Novel Therapeutic Targets
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT06680401
This study is trying to learn more about Epithelioid Haemangioendothelioma, a rare type of cancer, by collecting information on how it behaves and how well different treatments work.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (other) |
| Drugs / interventions | bevacizumab, apatinib, chemotherapy |
| Locations | 1 site (Milan) |
| Trial ID | NCT06680401 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on Epithelioid Haemangioendothelioma (EHE), a rare vascular soft tissue sarcoma, to gather extensive data on its clinical presentation, natural history, and treatment outcomes. The study aims to identify cytokines and hormones as potential biomarkers and to create patient-derived preclinical models for evaluating anticancer agents and validating new therapeutic targets. By analyzing the genetic translocations associated with EHE, the research seeks to enhance understanding of the disease and improve treatment strategies.
Who should consider this trial
Good fit: Ideal candidates include individuals with a histological diagnosis of EHE as per the 2020 WHO classification, regardless of age.
Not a fit: Patients unable to ensure adequate compliance with treatment or follow-up may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better diagnostic and therapeutic approaches for patients with EHE.
How similar studies have performed: While EHE is an ultra-rare condition, similar observational studies in rare cancers have shown promise in identifying biomarkers and improving treatment outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histological diagnosis of EHE according to 2020 WHO classification, performed on biopsy or surgical specimen * Signed informed consent * Adequate patient compliance to treatment or follow up * No age limit Exclusion Criteria: * Impossibility to ensure adequate compliance
Where this trial is running
Milan
- Fondazione IRCCS IstitutoNazionale dei Tumori — Milan, Italy (RECRUITING)
Study contacts
- Principal investigator: Silvia Stacchiotti — Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Study coordinator: Silvia Stacchiotti
- Email: Silvia.Stacchiotti@istitutotumori.mi.it
- Phone: 0223902803
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Clinical Presentation, Natural History, Treatment Outcomes